ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0042

Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity

Rahaf Baker1, Jonathan Graf2, Laura Trupin2, Sarah Goglin3, Patricia Katz4, Jennifer Barton5, Jean Liew6 and Katherine Wysham7, 1Highland Hospital Internal Medicine, Oakland, CA, 2UCSF, San Francisco, CA, 3University of California San Francisco, Burlingame, CA, 4University of California, San Francisco, Novato, CA, 5VAPORHCS/OHSU, Portland, OR, 6University of Washington, Seattle, WA, 7VA Puget Sound/University of Washington, Seattle, WA

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Disparities, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Although management of RA has improved greatly over the past two decades with the advent of novel therapeutics, racial/ethnic and socioeconomic disparities persist. Traditional RA disease activity measures, including the Clinical Disease Activity Index (CDAI) and DAS28-ESR, are influenced by provider and patient subjectivity which may impact racial/ethnic differences observed in prior studies. A multiple-biochemical measure of disease activity (MBDA) score, a composite of 12 serum biomarkers, was designed to be a more objective measure of RA disease activity. This study examined racial and ethnic differences in MBDA scores within a diverse cohort of RA patients.

Methods: Data are derived from the University of California, San Francisco RA Cohort, a longitudinal observational cohort, in which disease activity was measured as part of routine clinical care and MBDA was obtained at the time of each clinical encounter. All participants were from a safety-net hospital thereby reducing variations in income and insurance. Participants with ≥1 MBDA measure and self-reported race/ethnicity were included. Multivariable linear regression evaluated the association between race/ethnicity groups and mean MBDA score, adjusting for age at enrollment, sex, smoking history, RA symptom duration at enrollment, number of study visits, ACPA status, mean BMI, mean conventional DMARD (cDMARD) use, mean biologic DMARD (bDMARD) use and mean prednisone use. Missing data elements were estimated using multiple imputation with chained equations (MICE). Sensitivity analyses substituted CDAI and DAS28-ESR for the MBDA in multivariable linear regression models.

Results: There were 267 subjects, 86% female, mean age 52.7±13.3, and the majority were Hispanic (n=137, 51%) followed by Asian (n=91, 34%). Participants were followed an average 8.4±3.4 years and had moderate disease activity by all three measures (Table 1). After adjustment, Hispanic participants had the highest mean MBDA score (40.6), compared with White participants (33.0) (p=0.032). Black (36.2) participants had the second highest mean MBDA followed by Asian participants (36.0), although neither were significantly different from White participants (Table 2). The trends observed in the sensitivity analyses were similar to those in the primary analysis.

Conclusion: In a diverse observational RA cohort, Hispanic participants had the highest mean MBDA score, which was significantly higher than that of White participants after adjustment in the multivariable model. Black and Asian participants also had higher disease activity scores than White participants, although these differences did not reach statistical significance. Regardless of the method of assessment, racial/ethnic differences in disease activity are observed in RA. MBDA scores appear to add no additional information beyond standard, ACR-endorsed measures of disease activity in this analysis. Further studies focusing on early access to care, mitigating language barriers and addressing racial disparities should be done to enable improvement of disease outcomes across minority racial/ethnic groups.


Disclosure: R. Baker, None; J. Graf, None; L. Trupin, None; S. Goglin, None; P. Katz, None; J. Barton, None; J. Liew, None; K. Wysham, None.

To cite this abstract in AMA style:

Baker R, Graf J, Trupin L, Goglin S, Katz P, Barton J, Liew J, Wysham K. Racial and Ethnic Differences in a Multiple Biochemical Measure of Rheumatoid Arthritis Disease Activity [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/racial-and-ethnic-differences-in-a-multiple-biochemical-measure-of-rheumatoid-arthritis-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/racial-and-ethnic-differences-in-a-multiple-biochemical-measure-of-rheumatoid-arthritis-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology